Similarly, the dual PI3K-δ and PI3K-γ inhibitor duvelisib was shown in reverse phase protein arrays and immunoblots to increase BCL2 protein expression, increasing the sensitivity of ex vivo-cultured CLL cells obtained from duvelisib-treated patients to venetoclax [63]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.